Biotechnology company Alligator Bioscience (STO:ATORX) said on Thursday that it has decided to focus its resources on two proprietary candidate drugs, ATOR-1017 and mitazalimab.
Positive safety and strong Proof of Mechanism data support moving both of these potential new cancer treatments into clinical efficacy (Phase Ib/II) studies in 2021, the company said.
According to Alligator Bioscience CEO Per Norlén, ATOR-1017 and mitazalimab both have potential in "large cancer indications with high medical need and billion-dollar markets".
Alligator will complete the ongoing dose-escalation study with the bispecific ATOR-1015 as planned during the fourth quarter of 2020, after which it will be partnered for further development.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients